to treat advanced non-small-cell lung cancer (NSCLC) as a single agent or in combination with cisplatin, and approved in the European Union to treat NSCLC and advanced or metastatic breast cancer

Earlier this month, shares of Clovis (NASDAQ:CLVS) more than doubled following the company's presentation of data on targeted EGFR inhibitor CO-1686 in non-small-cell lung cancer at the American Society of Clinical Oncology meeting in Chicago

Tarceva Metastatic non-small-cell lung cancer Genentech Inc

lung cancer Initiated enrollment of the fourth dose level cohort of 0.46 mcg/kg in the ongoing Phase I/II study 5/31/13 Immunomedics Inc. (Morris Plains, N.J.) IMMU-130 and IMMU-132 Antibody-drug conjugates that involve SN-38, conjugated by technology to labetuzumab or the anti-TROP-2 humanized antibody, hRS7 Advanced solid tumors Phase I data showed tumor shrinkage, including partial responses 5/31/13 Isis Pharmaceuticals Inc. (Carlsbad, Calif.) ISIS-STAT3Rx An antisense drug Advanced

lung cancer Median overall survival was 25.6 months compared to 22.3 months for the placebo group...it missed the primary endpoint of overall survival 5/17/13 Peregrine Pharmaceuticals Inc. (Tustin, Calif.) Bavituximab Immunotherapy Non-small-cell lung cancer Reached agreement with the FDA on a Phase III registration trial 5/21/13 CARDIOVASCULAR Amag Pharmaceuticals Inc. (Lexington, Mass.) Feraheme Ferumoxytol Iron deficiency anemia Reported a new subgroup analysis for a Phase III trial of 231

an alpha particle-emitting radioactive therapeutic agent Castration-resistant prostate cancer FDA approved it 5/16/13 Aveo Oncology Inc. (Cambridge, Mass.) Tivozanib A once-daily, VEGF receptor tyrosine kinase inhibitor Advanced kidney cancer FDA committee voted 13-1 against approval of tivozanib 5/3/13 Genentech Inc. (South San Francisco; unit of Roche Group; Basel, Switzerland) and Astellas Pharma Inc. (Tokyo) Tarceva Erlotinib tablets Metastatic non-small-cell lung cancer FDA approved Tarceva

lung cancer An independent data safety monitoring committee recommended the company discontinue its Phase IIb trial because patients treated were unlikely to show progression-free survival over approved chemotherapeutic agents 5/9/13 Gilead Sciences Inc. (Foster City, Calif.) Ideslalisib (formerly GS-1101) Targeted, oral inhibitor of P13k delta Treatment-naive chronic lymphocytic leukemia Phase II data of idelalisib in combination with rituximab showed it achieved a complete response rate of 19

Debiopharm Group, of Lausanne, Switzerland, said it treated the first patients in a Phase I study of Debio 1143, a small-molecule neutralizing inhibitor of apoptosis protein, combined with carboplatin and paclitaxel in patients with squamous non-small-cell lung cancer, platinum-refractory ovarian cancer and basal-like/claudin low-triple-negative breast cancer

lung cancer 5/16/13 Notes: Currency conversions are based on exchange rates at the time of the deal

In the Phase I study, of 140 evaluable patients treated with the drug, 29 (21 percent) showed tumor shrinkage by RECIST criteria, with the highest responses in patients with non-small-cell lung cancer and melanoma

The company also has data showing that Adva-27a can kill other aggressive and multidrug-resistant cells including breast cancer, small-cell lung cancer and uterine sarcoma

Debiopharm Group, of Lausanne, Switzerland, said it treated the first patients in a Phase I study of Debio 1143, a small-molecule neutralizing inhibitor of apoptosis protein, combined with carboplatin and paclitaxel in patients with squamous non-small-cell lung cancer, platinum-refractory ovarian cancer and basal-like/claudin low-triple-negative breast cancer

The company also has data showing that Adva-27a can kill other aggressive and multidrug-resistant cells including breast cancer, small-cell lung cancer and uterine sarcoma

So it made sense to exclude those rapid progressors, an exclusion that has been seen in other cancer trials, including breast, ovarian and blood cancer studies, Bahcall said, "but is a new concept in lung cancer." "The Phase II trial was very large, kind of like a dress rehearsal for Phase III," he told BioWorld Today...Other studies are ongoing testing ganetespib as a monotherapy in ALK-positive non-small-cell lung cancer and in metastatic breast cancer, with data expected later this year

Inc., of Whitehouse Station, N.J., also reported findings from its PD-1 therapy, lambrolizumab (MK-3475), in melanoma, as the company prepares to launch late-stage trials in melanoma and non-small-cell lung cancer (NSCLC

In a third presentation, Ariad disclosed updated results from its tyrosine kinase inhibitor, AP26113, in patients with advanced non-small-cell lung cancer (NSCLC...In addition, AstraZeneca announced plans to initiate a Phase III trial in KRAS-mutant non-small-cell lung cancer in October 2013 and disclosed that they have already dosed the first patient in their ASTRA thyroid cancer registration trial

Analysts, inspecting early stage data, hailed the "paradigm-changing" potential in the treatment of at least one set of non-small-cell lung cancer (NSCLC) patients with Clovis Oncology Inc.'s oral CO-1686, for which results from Phase I/II trials were reported at ASCO 2013

NewLink presented data Saturday from a trial testing tergenpumatucel-L, a candidate emerging from the firm's HyperAcute immunotherapy platform, as a single-agent in 28 previously treated – second-line and third-line – patients with metastatic or recurrent non-small-cell lung cancer (NSCLC

The drug is being evaluated in non-small-cell lung cancer